

The background features a network of hexagons connected by lines, with some containing chemical formulas like '2C2H1111', '8C3H1111', 'C8H1111', and '4C2H11'. The letters H, E, R, and O are prominently displayed in white within these hexagons. A blue microscope lens is visible in the background, and a blue pill is shown in a petri dish.

H

E

R

O

YOU'VE GOT THE CANCER THERAPY. WE'VE GOT THE EARLY PHASE STUDY SOLUTION.

Imagine working with a team as dedicated to Early Phase oncology research as you are.

The HERO™ Initiative by Accelovance is designed to incubate and advance promising oncology research from Early Phase to market. Because HERO is dedicated exclusively to Early Phase oncology clinical research, your investment will benefit from best-in-class Early Phase oncology research services, from the design of the study protocol to the design of the business plan, and beyond.

Unlike other outsourced clinical research options, HERO™ by Accelovance is dedicated solely to Early Phase oncology.

The HERO™ Initiative isn't a 'feeder' into late-phase offerings. It's structured to support the unique needs of Early Phase research.

The HERO™ Initiative by Accelovance is a rare opportunity for small pharma and biotechs with promising compounds.

HERO™ is our pledge to create more fruitful relationships, deliver a higher degree of therapeutic expertise, and the opportunity to do better, more meaningful clinical research.

**ACCELERATE YOUR CANCER RESEARCH AT
[ACCELOVANCE.COM/HERO](https://www.accelovance.com/hero)**

A circular logo featuring a stylized 'Q' shape formed by four interlocking loops in blue, red, green, and orange.

THE **HERO** INITIATIVE
by  accelovance



DO YOU HAVE A COMPOUND OR THERAPY
THAT'S SHOWN SCIENTIFIC PROMISE?

HERO™ CAN TAKE YOUR WORK FROM TRIAL TO TREATMENT.

We're looking for the next big origin story in cancer treatment.

For us, cancer research is personal. It's more than a paycheck. It's more than the glory of a breakthrough. Just like you, the work we do each day is a tribute to our truest heroes—those we've loved, and lost to cancer.

That's why we created HERO™—and why we push for better outcomes and unparalleled performance in clinical research.

Study Start-Up in as Few as 8 Weeks

The industry average start-up time for oncology trials is six months. What are the odds yours can be up-and-running in half the time? With the advanced HERO™ site network, study start-ups can prevent up to \$1.5 million per day in lost revenue.

Funding & Venture Capital Network

The HERO™ Initiative by Accelovance creates unprecedented value for promising compounds and therapies. Our experienced pharmaceutical executive team has the resources and relationships to create new business connections for your Early Phase oncology research. As part of HERO™, we'll vet the business case for your compound or therapy, and make the introductions necessary to make your clinical trial possible.

Request a free, confidential review of your protocol or concept document, complete with operational, therapeutic, and strategic considerations at [accelovance.com/HERO](https://www.accelovance.com/HERO).

HELPING EARLY RESEARCH *in* ONCOLOGY

THE HERO™ INITIATIVE'S COMPLETE SUITE OF CRO SERVICES

- Biostatistics
- Clinical Call Center
- Clinical Trial Monitoring
- Data Management
- Medical Writing
- Pharmacovigilance
- Project Management
- Protocol Analysis
- Protocol Development
- Regulatory Affairs and IND Services

